LISA CONTE, Founder, President and CEO, Jaguar Health (NASD: JAGX).
Lisa Conte is the founder, president and chief executive officer, and a member of the board of directors, of Jaguar Health, a commercial-stage pharmaceuticals company committed to discovering, developing and commercializing plant-based prescription medicines for urgent global health needs.
Mytesi, the company’s FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, is a first-in-class, plant-based anti-secretory agent and the first oral drug approved under FDA Botanical Guidance.
In July 2017, two companies founded by Ms. Conte — Napo Pharmaceuticals, a human-focused pharmaceuticals company, and Jaguar Animal Health, the veterinary-focused licensor of all of Napo’s technology — merged and now comprise Jaguar Health.
In 1989, Ms. Conte also founded Shaman Pharmaceuticals, Inc. and has pioneered plant-based prescription medicine investigation and development for more than 30 years, including a recent Entheogen Therapeutics Initiative, looking at psychoactive plants for novel cures for mood disorders and CNS neurodegenerative diseases.
Ms. Conte is currently a member of the board of directors of Healing Forest Conservatory, and serves on the Editorial Advisory Board of Life Science Leader magazine.
She holds an M.S. in Physiology and Pharmacology from the University of California, San Diego, and an MBA and A.B. in Biochemistry from Dartmouth College.
In this extensive and wide ranging 4,170 word interview, exclusively in the Wall Street Transcript, Lisa Conte details the prospects for Jaguar Health (NASD: JAGX) and the upside for investors.
“Jaguar Health does all our drug discovery from plants used traditionally in tropical areas. So leveraging the knowledge of shamans and traditional healers to do more efficient drug discovery and development yielded a successful compound called crofelemer, which is commercialized as a product called Mytesi.
It’s a novel way of first-in-class mechanism of action for treating gastrointestinal disorders and normalizing gut function, and that is our mission, to use natural plant-based products to have new ways of treating and curing primarily gastrointestinal disorders.
And a further strategy and mission of the company is to mitigate the considerable risk associated with drug development by taking crofelemer, which is already approved by the FDA for a chronic indication, and looking at follow-on indications, follow-on patient populations, because the product is already approved, it’s already manufactured, it’s already used chronically. So it’s mitigating as much risk as possible to get it into other patient populations.”
Lisa Conte details the status of the novel drug treatmeant that Jaguar Health (NASD: JAGX) is producing:
“In humans, Phase III, as you know, is the final pivotal trial. Sometimes you have to do two, sometimes you have to do one. We had a discussion with the FDA — negotiation really — for about 18 months for a single pivotal trial for cancer therapy-related diarrhea in humans. And that’s what’s going on right now.
And that’s a major transformative moment for the company in support of the potential availability of crofelemer to much larger patient populations, and of course the potential financial return that goes to shareholders associated with that.
On the animal side, the conditional approval, because it’s MUMS, which is considered an orphan indication, the product can be sold right now, only for chemotherapy-induced diarrhea in dogs.
And we need to finish within a five-year period of time the complete approval, and we have to show progress towards that every single year or, at the end of five years, they take your conditional approval away.
And so those are a pivotal trial that will be agreed to with the FDA’s Center of Veterinary Medicine, and we’re in discussions with them now.
So I reserve the Phase I, II, III terminology for the human side and particularly since this is a conditional approval on the animal side, it’s more like conditional approval, pivotal full approval trial.”
Get all the details on the development of these novel drug developments by reading the entire 4,170 word interview with Lisa Conte, CEO of Jaguar Health (NASD: JAGX), exclusively in the Wall Street Transcript.
Lisa Conte, Founder, President & CEO
email: hello@jaguar.health
70 Pounds of Lithium in Each Tesla (NASD: TSLA) Fuels Christopher Jones' Westwater Resources (NASD: WWR)
December 11, 2017
Pamela Palmer, M.D., Ph.D., Has Developed a New Wonder Drug for her Company
October 10, 2019
Janet M. Brown, President and CEO of FundX Investment Group, Details Her Professional Portfolio Strategy
March 19, 2018
Vyant Bio (NASD: VYNT) is on the Cutting Edge of Biotech Drug Development
March 23, 2022
Jacob Johnson Identifies These Publicly Traded Companies That Make the Equipment for New Drug Discovery and Development
April 02, 2020
